Related Videos
Video
ESMO Breast Cancer 2026 Highlights: Saci-IO HR+
Harold Burstein, MD, PhD, and Ana C. Garrido-Castro, MD discuss results from the Saci-IO HR+ trial, which were presented at the 2026 ESMO Breast Cancer Congress.
Video
ESMO Breast Cancer 2026 Highlights: Pumitamig + DB-1305/BNT325
Harold Burstein, MD, PhD, and Ana C. Garrido-Castro, MD discuss results from the Pumitamig + DB-1305/BNT325 trial, which were presented at the 2026 ESMO Breast Cancer Congress.
Video
ESMO Breast Cancer 2026 Highlights Panel Discussion
Harold Burstein, MD, PhD; Sara Tolaney, MD, MPH; Erica L. Mayer, MD, MPH; Nancy Lin, MD; and Ana C. Garrido-Castro, MD discuss important breast cancer research presented at the 2026 ESMO Breast Cancer Congress.
Video
2025 San Antonio Breast Cancer Symposium Panel Discussion
Harold Burstein, MD, PhD; Sara Tolaney, MD, MPH; Nancy Lin, MD; Sarah Sammons, MD; Ana C. Garrido-Castro, MD; and Elizabeth Ann Mittendorf, MD, PhD, MHCM, discuss important breast cancer research presented at the 2025 San Antonio Breast Cancer Symposium.
Video
2025 SABCS Highlights: Advances in ADC's for Advanced Breast Cancer
Harold Burstein, MD, PhD, and Ana C. Garrido-Castro, MD, discuss the ASCENT-04, ASCENT-03, TROPION-Breast02, ASCENT-07, and OptiTROP-Breast02 trials researching antibody-drug conjugates (ADCs) for breast cancer.
Video
ESMO25 Breast Cancer Highlights: ASCENT-03 and TROPION-Breast02
Harold Burstein, MD, PhD, and Ana Garrido-Castro, MD, discuss the ASCENT-03 and TROPION-Breast02 trials, investigating antibody-drug conjugates for triple-negative breast cancer.
Video
Ana Garrido-Castro, MD Discusses SACI-IO HR+
Antibody-drug conjugate plus a checkpoint inhibitor shows a trend toward improved survival in PD-L1-positive hormone receptor-positive, HER2-negative breast cancer.